Cargando…

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterlo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benza, Raymond L., Langleben, David, Hemnes, Anna R., Vonk Noordegraaf, Anton, Rosenkranz, Stephan, Thenappan, Thenappan, Hassoun, Paul M., Preston, Ioana R., Ghio, Stefano, Badagliacca, Roberto, Vizza, Carmine D., Lang, Irene M., Meier, Christian, Grünig, Ekkehard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724805/ https://www.ncbi.nlm.nih.gov/pubmed/36198418 http://dx.doi.org/10.1183/16000617.0061-2022

Ejemplares similares

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update
por: Vonk Noordegraaf, Anton, et al.
Publicado: (2019)

Pulmonary Arterial Hypertension and Sex in the Right Ventricle: It Is an Interesting Picture!
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization
por: Thenappan, Thenappan
Publicado: (2017)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Badagliacca, Roberto, et al.
Publicado: (2021)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Late-onset pulmonary arterial hypertension in repaired D-transposition of great arteries: an uncommon complication
por: Baskaran, Janani, et al.
Publicado: (2017)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension
por: Forfia, Paul, et al.
Publicado: (2023)

Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Thenappan, Thenappan, et al.
Publicado: (2021)

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )
por: Dachs, Theresa Marie, et al.
Publicado: (2022)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Pulmonary hypertension
por: Vonk Noordegraaf, Anton, et al.
Publicado: (2016)

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
por: Prins, Kurt W., et al.
Publicado: (2018)

The WHO classification of pulmonary hypertension: A case-based imaging compendium
por: Ryan, John J., et al.
Publicado: (2012)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

Human Herpesvirus 8 and Pulmonary Hypertension
por: Nicastri, Emanuele, et al.
Publicado: (2005)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Imaging the heart in pulmonary hypertension: an update
por: Grünig, Ekkehard, et al.
Publicado: (2015)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
por: van Thor, M.C.J., et al.
Publicado: (2019)

Left ventricular heart failure and pulmonary hypertension(†)
por: Rosenkranz, Stephan, et al.
Publicado: (2016)

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
por: Hoeper, Marius M., et al.
Publicado: (2015)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6n952pta1hmjgh3u31ojnjrusp